On this page of StockholderLetter.com we present the latest annual shareholder letter from Xenon Pharmaceuticals Inc. — ticker symbol XENE. Reading current and past XENE letters to shareholders can bring important insights into the investment thesis.
XENON PHARMACEUTICALS INC. 2024 ANNUAL REPORT
/s/ Ian C. Mortimer /s/ Dawn Svoronos Certain statements contained in this letter may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and Canadian securities laws. A detailed discussion of such forward-looking statements and the related risks and uncertainties is included in our Annual Report on Form 10-K included herewith.
 • shareholder letter icon 4/24/2025 Letter Continued (Full PDF)
 • stockholder letter icon 4/27/2023 XENE Stockholder Letter
 • stockholder letter icon 4/26/2024 XENE Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon XENE Benford's Law Stock Score = 46


XENE Shareholder/Stockholder Letter Transcript:

XENON PHARMACEUTICALS INC.
2024 ANNUAL REPORT


/s/ Ian C. Mortimer
/s/ Dawn Svoronos
Certain statements contained in this letter may constitute forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and Canadian securities laws. A detailed
discussion of such forward-looking statements and the related risks and uncertainties is included in our Annual Report on Form 10-K
included herewith.




shareholder letter icon 4/24/2025 Letter Continued (Full PDF)
 

XENE Stockholder/Shareholder Letter (Xenon Pharmaceuticals Inc.) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.